Anp still flying under the radar - 4 weeks out from phase2 data for their acromegaly treatment. Although I think last time I posted here it was around 1.2c ( pre 10-1 consolidation) currently sitting around 16c. On positive data potential licensing would be between 200-300mill with upfront payment of approx 30 mill ( greater than our current mc).
Also tox study for their Ms drug will complete dosing by years end with results due early 2014. Again on clear tox study data this drug will go straight back into a phase2b study and be up against billion dollar a year Tysabri. Stem cell mobilisation trial also due to start 2Q 2014. This company of all the mini biotechs has one of the most advanced pipelines in Australia yet for a couple of false starts with licensing , continues to be overlooked by the wider market imo. Anyway with so many biotechs running off the charts but further back in development stages , Anp might be worth some consideration.
